tradingkey.logo
搜索

Regentis Biomaterials Ord Shs

RGNT
添加自选
2.148USD
+0.099+4.80%
收盘 05/15, 16:00美东报价延迟15分钟
11.13M总市值
--市盈率 TTM

Regentis Biomaterials Ord Shs

2.148
+0.099+4.80%

关于 Regentis Biomaterials Ord Shs 公司

Regentis Biomaterials Ltd is an Israel-based regenerative medicine company. The Company is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Its lead product is GellinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage. Its implant combines the precision of photopolymerization with the biocompatibility of PEG and fibrinogen, enabling natural tissue regeneration without the need for cell harvesting or culturing. Regentis Biomaterials Ltd aims to address unmet clinical needs in sports medicine and early-stage osteoarthritis.

Regentis Biomaterials Ord Shs简介

公司代码RGNT
公司名称Regentis Biomaterials Ltd
上市日期Dec 04, 2025
CEOHazum (Eli)
员工数量- -
证券类型Ordinary Share
年结日- -
公司地址60, Medinat Hyahudim
城市HERZLIYA
上市交易所NASDAQ OMX – NASDAQ Basic Amex
国家Israel
邮编4676652
电话97246265502
网址https://www.regentis.co.il/
公司代码RGNT
上市日期Dec 04, 2025
CEOHazum (Eli)

Regentis Biomaterials Ord Shs公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Dr. Ehud Geller, Ph.D.
Dr. Ehud Geller, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Eli Hazum
Dr. Eli Hazum
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Arie Gordashnikov, CPA
Mr. Arie Gordashnikov, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jeff Dykan, CPA
Mr. Jeff Dykan, CPA
Director
Director
--
--
Dr. Susan Alpert, M.D., Ph.D.
Dr. Susan Alpert, M.D., Ph.D.
Independent Director Nominee
Independent Director Nominee
--
--
Mr. Catherine C. (Keith) Valentine
Mr. Catherine C. (Keith) Valentine
Independent Director
Independent Director
--
--
Mr. Efraim Cohen-Arazi
Mr. Efraim Cohen-Arazi
Independent Director Nominee
Independent Director Nominee
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Mr. Pini Ben-Elazar
Mr. Pini Ben-Elazar
Independent Director Nominee
Independent Director Nominee
73.54K
--
Dr. Ehud Geller, Ph.D.
Dr. Ehud Geller, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Eli Hazum
Dr. Eli Hazum
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Arie Gordashnikov, CPA
Mr. Arie Gordashnikov, CPA
Chief Financial Officer
Chief Financial Officer
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 5月7日 周四
更新时间: 5月7日 周四
持股股东
股东类型
持股股东
持股股东
占比
HaisThera Scientific Fund I, L.P
11.90%
Vitalife Life Sciences Venture Capital
7.74%
Ocorian Fund Management S.a.r.l
5.72%
Medica Venture Partners
5.05%
DSM Venturing B.V.
5.04%
其他
64.54%
持股股东
持股股东
占比
HaisThera Scientific Fund I, L.P
11.90%
Vitalife Life Sciences Venture Capital
7.74%
Ocorian Fund Management S.a.r.l
5.72%
Medica Venture Partners
5.05%
DSM Venturing B.V.
5.04%
其他
64.54%
股东类型
持股股东
占比
Corporation
17.63%
Venture Capital
12.78%
Private Equity
9.28%
Hedge Fund
5.06%
Individual Investor
1.42%
其他
53.84%

机构持股

更新时间: 4月1日 周三
更新时间: 4月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2026Q1
8
1.40M
27.12%
+611.09K

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
HaisThera Scientific Fund I, L.P
616.61K
11.9%
+616.61K
--
Feb 20, 2026
Vitalife Life Sciences Venture Capital
400.94K
7.74%
+400.94K
--
Feb 20, 2026
Ocorian Fund Management S.a.r.l
296.37K
5.72%
+296.37K
--
Feb 20, 2026
Medica Venture Partners
261.78K
5.05%
-512.73K
-66.20%
Feb 20, 2026
DSM Venturing B.V.
261.02K
5.04%
+261.02K
--
Feb 20, 2026
Rosalind Advisors, Inc.
251.51K
4.86%
+251.51K
--
Dec 31, 2025
Ben-Elazar (Pini)
73.54K
1.42%
+73.54K
--
Feb 20, 2026
Citadel Advisors LLC
10.41K
0.2%
+10.41K
--
Dec 31, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
KeyAI